The next 20 years of human genomics must be more equitable and more open
By Nature Staff,
Nature
| 02. 10. 2021
The first drafts of the human genome, published in Nature and Science 20 years ago, flung open the doors for what some predicted would be ‘biology’s century’. In just one-fifth of the century, the corpus of information has grown from two gappy and error-filled genome sequences to a full account of the genetic variation of hundreds of thousands of individuals around the world, and an increasing number of tools to study it. This special issue of Nature examines how far the human genome sequence has taken us, and how far we have to go. But some aspects of the research ecosystem around the human genome have hardly changed, and that remains a concern.
Many of the ethical, legal and social implications of genome research — including questions of privacy, informed consent and equitable representation of researchers and participants — remain unresolved. Moreover, free and open access to genome data remains unevenly implemented. Just this week, researchers pointed out the problems caused by lack of accessibility to coronavirus genomes in the middle of a pandemic. Researchers, funders and journals will...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...